<!DOCTYPE html>
<html lang="en-US">
  <!-- Mirrored from bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/ by HTTrack Website Copier/3.x [XR&CO'2014], Wed, 18 Dec 2024 11:01:49 GMT -->
  <!-- Added by HTTrack --><meta
    http-equiv="content-type"
    content="text/html;charset=UTF-8"
  /><!-- /Added by HTTrack -->
  <head>
    <title>Second Quarter 2022 Financial Results | BridgeBio</title>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta
      name="viewport"
      content="width=device-width, initial-scale=1, maximum-scale=5.0, minimum-scale=1"
    />
    <meta
      name="robots"
      content="index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1"
    />

    <!-- This site is optimized with the Yoast SEO plugin v23.4 - https://yoast.com/wordpress/plugins/seo/ -->
    <meta
      name="description"
      content="BridgeBio reported its financial results for the second quarter ended June 30, 2022, and provided an update on the Company’s operations. Learn more."
    />
    <link rel="canonical" href="index.html" />
    <meta property="og:locale" content="en_US" />
    <meta property="og:type" content="article" />
    <meta
      property="og:title"
      content="Second Quarter 2022 Financial Results | BridgeBio"
    />
    <meta
      property="og:description"
      content="BridgeBio reported its financial results for the second quarter ended June 30, 2022, and provided an update on the Company’s operations. Learn more."
    />
    <meta property="og:url" content="index.html" />
    <meta property="og:site_name" content="BridgeBio" />
    <meta
      property="article:published_time"
      content="2022-08-04T11:30:27+00:00"
    />
    <meta
      property="article:modified_time"
      content="2022-12-02T19:27:25+00:00"
    />
    <meta
      property="og:image"
      content="../../wp-content/uploads/2022/08/BBIO_Q2_1.png"
    />
    <meta name="author" content="Holly Condon" />
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:creator" content="@BridgeBioPharma" />
    <meta name="twitter:site" content="@BridgeBioPharma" />
    <meta name="twitter:label1" content="Written by" />
    <meta name="twitter:data1" content="Holly Condon" />
    <meta name="twitter:label2" content="Est. reading time" />
    <meta name="twitter:data2" content="20 minutes" />
    <script type="application/ld+json" class="yoast-schema-graph">
      {
        "@context": "https://schema.org",
        "@graph": [
          {
            "@type": "WebPage",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/",
            "url": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/",
            "name": "Second Quarter 2022 Financial Results | BridgeBio",
            "isPartOf": { "@id": "https://bridgebio.com/#website" },
            "primaryImageOfPage": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/#primaryimage"
            },
            "image": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/#primaryimage"
            },
            "thumbnailUrl": "http://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_1.png",
            "datePublished": "2022-08-04T11:30:27+00:00",
            "dateModified": "2022-12-02T19:27:25+00:00",
            "author": {
              "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca"
            },
            "description": "BridgeBio reported its financial results for the second quarter ended June 30, 2022, and provided an update on the Company’s operations. Learn more.",
            "breadcrumb": {
              "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/#breadcrumb"
            },
            "inLanguage": "en-US",
            "potentialAction": [
              {
                "@type": "ReadAction",
                "target": [
                  "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/"
                ]
              }
            ]
          },
          {
            "@type": "ImageObject",
            "inLanguage": "en-US",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/#primaryimage",
            "url": "https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_1.png",
            "contentUrl": "https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_1.png",
            "width": 785,
            "height": 780
          },
          {
            "@type": "BreadcrumbList",
            "@id": "https://bridgebio.com/news/bridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update/#breadcrumb",
            "itemListElement": [
              {
                "@type": "ListItem",
                "position": 1,
                "name": "Home",
                "item": "https://bridgebio.com/"
              },
              {
                "@type": "ListItem",
                "position": 2,
                "name": "BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update "
              }
            ]
          },
          {
            "@type": "WebSite",
            "@id": "https://bridgebio.com/#website",
            "url": "https://bridgebio.com/",
            "name": "BridgeBio",
            "description": "",
            "potentialAction": [
              {
                "@type": "SearchAction",
                "target": {
                  "@type": "EntryPoint",
                  "urlTemplate": "https://bridgebio.com/?s={search_term_string}"
                },
                "query-input": {
                  "@type": "PropertyValueSpecification",
                  "valueRequired": true,
                  "valueName": "search_term_string"
                }
              }
            ],
            "inLanguage": "en-US"
          },
          {
            "@type": "Person",
            "@id": "https://bridgebio.com/#/schema/person/e56e9128cd840531b0acdca992cb1fca",
            "name": "Holly Condon",
            "image": {
              "@type": "ImageObject",
              "inLanguage": "en-US",
              "@id": "https://bridgebio.com/#/schema/person/image/",
              "url": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "contentUrl": "https://secure.gravatar.com/avatar/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g",
              "caption": "Holly Condon"
            },
            "url": "https://bridgebio.com/author/hcondon/"
          }
        ]
      }
    </script>
    <!-- / Yoast SEO plugin. -->

    <link rel="dns-prefetch" href="http://cdnjs.cloudflare.com/" />
    <link rel="dns-prefetch" href="http://unpkg.com/" />
    <link rel="dns-prefetch" href="http://fonts.googleapis.com/" />
    <link
      rel="alternate"
      type="application/rss+xml"
      title="BridgeBio &raquo; BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update  Comments Feed"
      href="feed/index.html"
    />
    <script type="text/javascript">
      /* <![CDATA[ */
      window._wpemojiSettings = {
        baseUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/",
        ext: ".png",
        svgUrl: "https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/",
        svgExt: ".svg",
        source: {
          concatemoji:
            "https:\/\/bridgebio.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.6.2",
        },
      };
      /*! This file is auto-generated */
      !(function (i, n) {
        var o, s, e;
        function c(e) {
          try {
            var t = { supportTests: e, timestamp: new Date().valueOf() };
            sessionStorage.setItem(o, JSON.stringify(t));
          } catch (e) {}
        }
        function p(e, t, n) {
          e.clearRect(0, 0, e.canvas.width, e.canvas.height),
            e.fillText(t, 0, 0);
          var t = new Uint32Array(
              e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
            ),
            r =
              (e.clearRect(0, 0, e.canvas.width, e.canvas.height),
              e.fillText(n, 0, 0),
              new Uint32Array(
                e.getImageData(0, 0, e.canvas.width, e.canvas.height).data
              ));
          return t.every(function (e, t) {
            return e === r[t];
          });
        }
        function u(e, t, n) {
          switch (t) {
            case "flag":
              return n(
                e,
                "\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f",
                "\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f"
              )
                ? !1
                : !n(
                    e,
                    "\ud83c\uddfa\ud83c\uddf3",
                    "\ud83c\uddfa\u200b\ud83c\uddf3"
                  ) &&
                    !n(
                      e,
                      "\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f",
                      "\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f"
                    );
            case "emoji":
              return !n(
                e,
                "\ud83d\udc26\u200d\u2b1b",
                "\ud83d\udc26\u200b\u2b1b"
              );
          }
          return !1;
        }
        function f(e, t, n) {
          var r =
              "undefined" != typeof WorkerGlobalScope &&
              self instanceof WorkerGlobalScope
                ? new OffscreenCanvas(300, 150)
                : i.createElement("canvas"),
            a = r.getContext("2d", { willReadFrequently: !0 }),
            o = ((a.textBaseline = "top"), (a.font = "600 32px Arial"), {});
          return (
            e.forEach(function (e) {
              o[e] = t(a, e, n);
            }),
            o
          );
        }
        function t(e) {
          var t = i.createElement("script");
          (t.src = e), (t.defer = !0), i.head.appendChild(t);
        }
        "undefined" != typeof Promise &&
          ((o = "wpEmojiSettingsSupports"),
          (s = ["flag", "emoji"]),
          (n.supports = { everything: !0, everythingExceptFlag: !0 }),
          (e = new Promise(function (e) {
            i.addEventListener("DOMContentLoaded", e, { once: !0 });
          })),
          new Promise(function (t) {
            var n = (function () {
              try {
                var e = JSON.parse(sessionStorage.getItem(o));
                if (
                  "object" == typeof e &&
                  "number" == typeof e.timestamp &&
                  new Date().valueOf() < e.timestamp + 604800 &&
                  "object" == typeof e.supportTests
                )
                  return e.supportTests;
              } catch (e) {}
              return null;
            })();
            if (!n) {
              if (
                "undefined" != typeof Worker &&
                "undefined" != typeof OffscreenCanvas &&
                "undefined" != typeof URL &&
                URL.createObjectURL &&
                "undefined" != typeof Blob
              )
                try {
                  var e =
                      "postMessage(" +
                      f.toString() +
                      "(" +
                      [JSON.stringify(s), u.toString(), p.toString()].join(
                        ","
                      ) +
                      "));",
                    r = new Blob([e], { type: "text/javascript" }),
                    a = new Worker(URL.createObjectURL(r), {
                      name: "wpTestEmojiSupports",
                    });
                  return void (a.onmessage = function (e) {
                    c((n = e.data)), a.terminate(), t(n);
                  });
                } catch (e) {}
              c((n = f(s, u, p)));
            }
            t(n);
          })
            .then(function (e) {
              for (var t in e)
                (n.supports[t] = e[t]),
                  (n.supports.everything =
                    n.supports.everything && n.supports[t]),
                  "flag" !== t &&
                    (n.supports.everythingExceptFlag =
                      n.supports.everythingExceptFlag && n.supports[t]);
              (n.supports.everythingExceptFlag =
                n.supports.everythingExceptFlag && !n.supports.flag),
                (n.DOMReady = !1),
                (n.readyCallback = function () {
                  n.DOMReady = !0;
                });
            })
            .then(function () {
              return e;
            })
            .then(function () {
              var e;
              n.supports.everything ||
                (n.readyCallback(),
                (e = n.source || {}).concatemoji
                  ? t(e.concatemoji)
                  : e.wpemoji && e.twemoji && (t(e.twemoji), t(e.wpemoji)));
            }));
      })((window, document), window._wpemojiSettings);
      /* ]]> */
    </script>
    <style id="wp-emoji-styles-inline-css" type="text/css">
      img.wp-smiley,
      img.emoji {
        display: inline !important;
        border: none !important;
        box-shadow: none !important;
        height: 1em !important;
        width: 1em !important;
        margin: 0 0.07em !important;
        vertical-align: -0.1em !important;
        background: none !important;
        padding: 0 !important;
      }
    </style>
    <style id="classic-theme-styles-inline-css" type="text/css">
      /*! This file is auto-generated */
      .wp-block-button__link {
        color: #fff;
        background-color: #32373c;
        border-radius: 9999px;
        box-shadow: none;
        text-decoration: none;
        padding: calc(0.667em + 2px) calc(1.333em + 2px);
        font-size: 1.125em;
      }
      .wp-block-file__button {
        background: #32373c;
        color: #fff;
        text-decoration: none;
      }
    </style>
    <style id="global-styles-inline-css" type="text/css">
      :root {
        --wp--preset--aspect-ratio--square: 1;
        --wp--preset--aspect-ratio--4-3: 4/3;
        --wp--preset--aspect-ratio--3-4: 3/4;
        --wp--preset--aspect-ratio--3-2: 3/2;
        --wp--preset--aspect-ratio--2-3: 2/3;
        --wp--preset--aspect-ratio--16-9: 16/9;
        --wp--preset--aspect-ratio--9-16: 9/16;
        --wp--preset--color--black: #000000;
        --wp--preset--color--cyan-bluish-gray: #abb8c3;
        --wp--preset--color--white: #ffffff;
        --wp--preset--color--pale-pink: #f78da7;
        --wp--preset--color--vivid-red: #cf2e2e;
        --wp--preset--color--luminous-vivid-orange: #ff6900;
        --wp--preset--color--luminous-vivid-amber: #fcb900;
        --wp--preset--color--light-green-cyan: #7bdcb5;
        --wp--preset--color--vivid-green-cyan: #00d084;
        --wp--preset--color--pale-cyan-blue: #8ed1fc;
        --wp--preset--color--vivid-cyan-blue: #0693e3;
        --wp--preset--color--vivid-purple: #9b51e0;
        --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(
          135deg,
          rgba(6, 147, 227, 1) 0%,
          rgb(155, 81, 224) 100%
        );
        --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(
          135deg,
          rgb(122, 220, 180) 0%,
          rgb(0, 208, 130) 100%
        );
        --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(
          135deg,
          rgba(252, 185, 0, 1) 0%,
          rgba(255, 105, 0, 1) 100%
        );
        --wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(
          135deg,
          rgba(255, 105, 0, 1) 0%,
          rgb(207, 46, 46) 100%
        );
        --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(
          135deg,
          rgb(238, 238, 238) 0%,
          rgb(169, 184, 195) 100%
        );
        --wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(
          135deg,
          rgb(74, 234, 220) 0%,
          rgb(151, 120, 209) 20%,
          rgb(207, 42, 186) 40%,
          rgb(238, 44, 130) 60%,
          rgb(251, 105, 98) 80%,
          rgb(254, 248, 76) 100%
        );
        --wp--preset--gradient--blush-light-purple: linear-gradient(
          135deg,
          rgb(255, 206, 236) 0%,
          rgb(152, 150, 240) 100%
        );
        --wp--preset--gradient--blush-bordeaux: linear-gradient(
          135deg,
          rgb(254, 205, 165) 0%,
          rgb(254, 45, 45) 50%,
          rgb(107, 0, 62) 100%
        );
        --wp--preset--gradient--luminous-dusk: linear-gradient(
          135deg,
          rgb(255, 203, 112) 0%,
          rgb(199, 81, 192) 50%,
          rgb(65, 88, 208) 100%
        );
        --wp--preset--gradient--pale-ocean: linear-gradient(
          135deg,
          rgb(255, 245, 203) 0%,
          rgb(182, 227, 212) 50%,
          rgb(51, 167, 181) 100%
        );
        --wp--preset--gradient--electric-grass: linear-gradient(
          135deg,
          rgb(202, 248, 128) 0%,
          rgb(113, 206, 126) 100%
        );
        --wp--preset--gradient--midnight: linear-gradient(
          135deg,
          rgb(2, 3, 129) 0%,
          rgb(40, 116, 252) 100%
        );
        --wp--preset--font-size--small: 13px;
        --wp--preset--font-size--medium: 20px;
        --wp--preset--font-size--large: 36px;
        --wp--preset--font-size--x-large: 42px;
        --wp--preset--spacing--20: 0.44rem;
        --wp--preset--spacing--30: 0.67rem;
        --wp--preset--spacing--40: 1rem;
        --wp--preset--spacing--50: 1.5rem;
        --wp--preset--spacing--60: 2.25rem;
        --wp--preset--spacing--70: 3.38rem;
        --wp--preset--spacing--80: 5.06rem;
        --wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);
        --wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);
        --wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1),
          6px 6px rgba(0, 0, 0, 1);
        --wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);
      }
      :where(.is-layout-flex) {
        gap: 0.5em;
      }
      :where(.is-layout-grid) {
        gap: 0.5em;
      }
      body .is-layout-flex {
        display: flex;
      }
      .is-layout-flex {
        flex-wrap: wrap;
        align-items: center;
      }
      .is-layout-flex > :is(*, div) {
        margin: 0;
      }
      body .is-layout-grid {
        display: grid;
      }
      .is-layout-grid > :is(*, div) {
        margin: 0;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      .has-black-color {
        color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-color {
        color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-color {
        color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-color {
        color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-color {
        color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-color {
        color: var(--wp--preset--color--luminous-vivid-orange) !important;
      }
      .has-luminous-vivid-amber-color {
        color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-color {
        color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-color {
        color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-color {
        color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-color {
        color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-color {
        color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-background-color {
        background-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-background-color {
        background-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-background-color {
        background-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-background-color {
        background-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-background-color {
        background-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-background-color {
        background-color: var(
          --wp--preset--color--luminous-vivid-amber
        ) !important;
      }
      .has-light-green-cyan-background-color {
        background-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-background-color {
        background-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-background-color {
        background-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-background-color {
        background-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-background-color {
        background-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-black-border-color {
        border-color: var(--wp--preset--color--black) !important;
      }
      .has-cyan-bluish-gray-border-color {
        border-color: var(--wp--preset--color--cyan-bluish-gray) !important;
      }
      .has-white-border-color {
        border-color: var(--wp--preset--color--white) !important;
      }
      .has-pale-pink-border-color {
        border-color: var(--wp--preset--color--pale-pink) !important;
      }
      .has-vivid-red-border-color {
        border-color: var(--wp--preset--color--vivid-red) !important;
      }
      .has-luminous-vivid-orange-border-color {
        border-color: var(
          --wp--preset--color--luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-amber-border-color {
        border-color: var(--wp--preset--color--luminous-vivid-amber) !important;
      }
      .has-light-green-cyan-border-color {
        border-color: var(--wp--preset--color--light-green-cyan) !important;
      }
      .has-vivid-green-cyan-border-color {
        border-color: var(--wp--preset--color--vivid-green-cyan) !important;
      }
      .has-pale-cyan-blue-border-color {
        border-color: var(--wp--preset--color--pale-cyan-blue) !important;
      }
      .has-vivid-cyan-blue-border-color {
        border-color: var(--wp--preset--color--vivid-cyan-blue) !important;
      }
      .has-vivid-purple-border-color {
        border-color: var(--wp--preset--color--vivid-purple) !important;
      }
      .has-vivid-cyan-blue-to-vivid-purple-gradient-background {
        background: var(
          --wp--preset--gradient--vivid-cyan-blue-to-vivid-purple
        ) !important;
      }
      .has-light-green-cyan-to-vivid-green-cyan-gradient-background {
        background: var(
          --wp--preset--gradient--light-green-cyan-to-vivid-green-cyan
        ) !important;
      }
      .has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange
        ) !important;
      }
      .has-luminous-vivid-orange-to-vivid-red-gradient-background {
        background: var(
          --wp--preset--gradient--luminous-vivid-orange-to-vivid-red
        ) !important;
      }
      .has-very-light-gray-to-cyan-bluish-gray-gradient-background {
        background: var(
          --wp--preset--gradient--very-light-gray-to-cyan-bluish-gray
        ) !important;
      }
      .has-cool-to-warm-spectrum-gradient-background {
        background: var(
          --wp--preset--gradient--cool-to-warm-spectrum
        ) !important;
      }
      .has-blush-light-purple-gradient-background {
        background: var(--wp--preset--gradient--blush-light-purple) !important;
      }
      .has-blush-bordeaux-gradient-background {
        background: var(--wp--preset--gradient--blush-bordeaux) !important;
      }
      .has-luminous-dusk-gradient-background {
        background: var(--wp--preset--gradient--luminous-dusk) !important;
      }
      .has-pale-ocean-gradient-background {
        background: var(--wp--preset--gradient--pale-ocean) !important;
      }
      .has-electric-grass-gradient-background {
        background: var(--wp--preset--gradient--electric-grass) !important;
      }
      .has-midnight-gradient-background {
        background: var(--wp--preset--gradient--midnight) !important;
      }
      .has-small-font-size {
        font-size: var(--wp--preset--font-size--small) !important;
      }
      .has-medium-font-size {
        font-size: var(--wp--preset--font-size--medium) !important;
      }
      .has-large-font-size {
        font-size: var(--wp--preset--font-size--large) !important;
      }
      .has-x-large-font-size {
        font-size: var(--wp--preset--font-size--x-large) !important;
      }
      :where(.wp-block-post-template.is-layout-flex) {
        gap: 1.25em;
      }
      :where(.wp-block-post-template.is-layout-grid) {
        gap: 1.25em;
      }
      :where(.wp-block-columns.is-layout-flex) {
        gap: 2em;
      }
      :where(.wp-block-columns.is-layout-grid) {
        gap: 2em;
      }
      :root :where(.wp-block-pullquote) {
        font-size: 1.5em;
        line-height: 1.6;
      }
    </style>
    <link
      rel="stylesheet"
      id="google-fonts-css"
      href="https://fonts.googleapis.com/css2?family=Source+Sans+Pro:wght@300;400;700&amp;display=swap"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="slick-css-css"
      href="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="aos-css-css"
      href="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.css?ver=6.6.2"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="main-styles-css"
      href="../../wp-content/themes/bridgebio/styleaf1d.css?ver=1734518700"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="secondary-styles-css"
      href="../../wp-content/themes/bridgebio/assets/css/secondary-cssaf1d.css?ver=1734518700"
      type="text/css"
      media="all"
    />
    <link
      rel="stylesheet"
      id="onetrust-css"
      href="../../wp-content/themes/bridgebio/assets/css/onetrustaf1d.css?ver=1734518700"
      type="text/css"
      media="all"
    />
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery.minf43b.js?ver=3.7.1"
      id="jquery-core-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-includes/js/jquery/jquery-migrate.min5589.js?ver=3.4.1"
      id="jquery-migrate-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/scriptsaf1d.js?ver=1734518700"
      id="theme-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../cdnjs.cloudflare.com/ajax/libs/slick-carousel/1.8.1/slick109c.js?ver=6.6.2"
      id="slick-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../../unpkg.com/aos%403.0.0-beta.6/dist/aos.js?ver=6.6.2"
      id="aos-scripts-js"
    ></script>
    <script
      type="text/javascript"
      src="../../wp-content/themes/bridgebio/assets/js/modalaf1d.js?ver=1734518700"
      id="modal-js"
    ></script>
    <link rel="https://api.w.org/" href="../../wp-json/index.html" />
    <link
      rel="alternate"
      title="JSON"
      type="application/json"
      href="../../wp-json/wp/v2/posts/5713.json"
    />
    <link
      rel="EditURI"
      type="application/rsd+xml"
      title="RSD"
      href="../../xmlrpc0db0.php?rsd"
    />
    <link rel="shortlink" href="../../indexefd9.html?p=5713" />
    <link
      rel="alternate"
      title="oEmbed (JSON)"
      type="application/json+oembed"
      href="../../wp-json/oembed/1.0/embedcdb5.json?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update%2F"
    />
    <link
      rel="alternate"
      title="oEmbed (XML)"
      type="text/xml+oembed"
      href="../../wp-json/oembed/1.0/embed713a?url=https%3A%2F%2Fbridgebio.com%2Fnews%2Fbridgebio-pharma-inc-reports-second-quarter-2022-financial-results-and-business-update%2F&amp;format=xml"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-32x32.png"
      sizes="32x32"
    />
    <link
      rel="icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-192x192.png"
      sizes="192x192"
    />
    <link
      rel="apple-touch-icon"
      href="../../wp-content/uploads/2024/02/cropped-cropped-favicon-180x180.png"
    />
    <meta
      name="msapplication-TileImage"
      content="https://bridgebio.com/wp-content/uploads/2024/02/cropped-cropped-favicon-270x270.png"
    />
    <!-- OneTrust Cookies Consent Notice start for www.bridgebio.com -->
    <script
      src="../../../cdn.cookielaw.org/scripttemplates/otSDKStub.js"
      type="text/javascript"
      charset="UTF-8"
      data-domain-script="0191509e-107d-7797-bc76-f2cb533e79d3"
    ></script>
    <script type="text/javascript">
      function OptanonWrapper() {}
    </script>
    <!-- End OneTrust -->
    <!-- Google Tag Manager -->
    <script>
      (function (w, d, s, l, i) {
        w[l] = w[l] || [];
        w[l].push({ "gtm.start": new Date().getTime(), event: "gtm.js" });
        var f = d.getElementsByTagName(s)[0],
          j = d.createElement(s),
          dl = l != "dataLayer" ? "&l=" + l : "";
        j.async = true;
        j.src = "../../../www.googletagmanager.com/gtm5445.html?id=" + i + dl;
        f.parentNode.insertBefore(j, f);
      })(window, document, "script", "dataLayer", "GTM-T94V2KL");
    </script>
    <!-- End Google Tag Manager -->
    <!-- Marker.io Script -->
    <script>
      window.markerConfig = {
        project: "66622db13004831ec32eb666",
        source: "snippet",
      };
      !(function (e, r, a) {
        if (!e.__Marker) {
          e.__Marker = {};
          var t = [],
            n = { __cs: t };
          [
            "show",
            "hide",
            "isVisible",
            "capture",
            "cancelCapture",
            "unload",
            "reload",
            "isExtensionInstalled",
            "setReporter",
            "setCustomData",
            "on",
            "off",
          ].forEach(function (e) {
            n[e] = function () {
              var r = Array.prototype.slice.call(arguments);
              r.unshift(e), t.push(r);
            };
          }),
            (e.Marker = n);
          var s = r.createElement("script");
          (s.async = 1), (s.src = "../../../edge.marker.io/latest/shim.js");
          var i = r.getElementsByTagName("script")[0];
          i.parentNode.insertBefore(s, i);
        }
      })(window, document);
    </script>
    <!-- End Marker.io Script -->
  </head>

  <body
    class="post-template-default single single-post postid-5713 single-format-standard"
  >
    <!-- Google Tag Manager (noscript) -->
    <noscript
      ><iframe
        src="https://www.googletagmanager.com/ns.html?id=GTM-T94V2KL"
        height="0"
        width="0"
        style="display: none; visibility: hidden"
      ></iframe
    ></noscript>
    <!-- End Google Tag Manager (noscript) -->

    <nav
      class="nav nav--secondary nav--dark"
      style="--navbar-bg-color: transparent; position: relative"
    >
      <div class="nav--bg-color"></div>
      <div class="nav__content-wrapper">
        <div class="nav__menu-takeover"></div>
        <div class="nav__logo-container">
          <a href="../../index.html" class="" data-ol-has-click-handler="">
            <img
              src="../../bridge logo.webp"
              class="nav__logo hide-me"
              alt="BridgeBio logo"
            />
            <img
              src="../../bridge logo.webp"
              class="nav__logo"
              alt="BridgeBio logo"
            />
          </a>
        </div>
        <ul class="nav__menu">
          <li
            id="menu-item-4126"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4126"
          >
            <a href="../../about-us/index.html">about us</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6716"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6716"
              >
                <a href="../../about-us/index.html">overview</a>
              </li>
              <li
                id="menu-item-4093"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4093"
              >
                <a href="../../people/index.html">people</a>
              </li>
              <li
                id="menu-item-5080"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-5080"
              >
                <a href="../../partners/index.html">partners</a>
              </li>
              <li
                id="menu-item-4159"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-4159"
              >
                <a href="../../careers/index.html">careers</a>
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6309"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-6309"
          >
            <a href="../../pipeline/index.html">science &#038; pipeline</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6302"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6302"
              >
                <a href="../../pipeline/index.html#pipeline">pipeline</a>
              </li>
              <li
                id="menu-item-6306"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6306"
              >
                <a href="../../publications/index.html">publications</a>
              </li>
              <li
                id="menu-item-6315"
                class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6315"
              >
                <a href="../../licensing-opportunities.html"
                  >licensing opportunities</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6848"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6848"
          >
            <a href="#">products</a>
            <ul class="sub-menu">
              <li
                id="menu-item-7104"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7104"
              >
                <a
                  target="_blank"
                  rel="noopener"
                  href="https://www.attruby.com/"
                  >Attruby</a
                >
              </li>
              <li
                id="menu-item-6852"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6852"
              >
                <a target="_blank" rel="noopener" href="https://nulibry.com/"
                  >Nulibry</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-4316"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-4316"
          >
            <a href="../../patients-and-families/index.html"
              >patients &#038; families</a
            >
            <ul class="sub-menu">
              <li
                id="menu-item-7043"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7043"
              >
                <a href="../../patients-and-families/alexis/index.html"
                  >Alexis’ story</a
                >
              </li>
              <li
                id="menu-item-7044"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7044"
              >
                <a href="../../patients-and-families/elliott/index.html"
                  >Elliott’s story</a
                >
              </li>
              <li
                id="menu-item-7045"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7045"
              >
                <a href="../../patients-and-families/miguel/index.html"
                  >Miguel’s story</a
                >
              </li>
              <li
                id="menu-item-7046"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7046"
              >
                <a href="../../patients-and-families/tobin/index.html"
                  >Tobin’s story</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6296"
            class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-6296"
          >
            <a href="https://investor.bridgebio.com/">for investors</a>
            <ul class="sub-menu">
              <li
                id="menu-item-6297"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6297"
              >
                <a href="https://investor.bridgebio.com/press-releases"
                  >press releases</a
                >
              </li>
              <li
                id="menu-item-6298"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6298"
              >
                <a
                  href="https://investor.bridgebio.com/news-and-events/event-calendar"
                  >events</a
                >
              </li>
              <li
                id="menu-item-6303"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6303"
              >
                <a href="https://investor.bridgebio.com/presentations"
                  >presentations</a
                >
              </li>
              <li
                id="menu-item-6299"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6299"
              >
                <a
                  href="https://investor.bridgebio.com/financials-and-filings/sec-filings"
                  >SEC filings</a
                >
              </li>
              <li
                id="menu-item-6300"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6300"
              >
                <a href="https://investor.bridgebio.com/corporate-governance"
                  >corporate governance</a
                >
              </li>
              <li
                id="menu-item-6301"
                class="menu-item menu-item-type-custom menu-item-object-custom menu-item-6301"
              >
                <a
                  href="https://investor.bridgebio.com/stock-information/analyst-coverage"
                  >analyst coverage</a
                >
              </li>
            </ul>
          </li>
          <li
            id="menu-item-6295"
            class="menu-item menu-item-type-post_type menu-item-object-page menu-item-6295"
          >
            <a href="../index.html">news</a>
          </li>
        </ul>
        <button class="nav__toggle-button" data-ol-has-click-handler="">
          <div id="hamburger"><span></span><span></span><span></span></div>
          <div id="cross"><span></span><span></span></div>
        </button>
      </div>
    </nav>
    <main class="news-detail">
      <div class="flex-row">
        <div class="flex-column two-three">
          <article class="news-detail__post-content">
            <h1 class="page__title titlecase">
              BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial
              Results and Business Update 
            </h1>
            <section>
              <p>
                <em
                  >&#8211; Reported positive interim Phase 2 data for
                  infigratinib in achondroplasia demonstrating a mean increase
                  in annualized height velocity (AHV) of 1.52 cm/year among all
                  Cohort 4 children 5 years of age and older, and announced
                  addition of a 5<sup>th</sup> cohort to the trial</em
                >
              </p>
              <p>
                <em
                  >&#8211; Reported positive Phase 2 data for encaleret in
                  autosomal dominant hypocalcemia type 1 (ADH1) and announced
                  design of the Phase 3 pivotal study, which is expected to
                  begin later this year</em
                >
              </p>
              <p>
                <em> </em><em>&#8211;</em
                ><em>
                  Selected a next-generation KRAS G12C dual inhibitor
                  development candidate and plan to be in the clinic in
                  mid-2023</em
                >
              </p>
              <p>
                <em> </em
                ><em
                  >&#8211; Presented updated results from the open-label
                  extension of the Phase 2 study of acoramidis in transthyretin
                  amyloid cardiomyopathy (ATTR-CM), which continue to suggest
                  long-term tolerability of acoramidis and stabilization of
                  disease progression in ATTR-CM
                </em>
              </p>
              <p>
                <em
                  >&#8211; Reported positive data for five early-to-mid-stage
                  genetic disease programs in pipeline, including primary
                  hyperoxaluria type 1 (PH1) and recurrent kidney stone
                  formation; Canavan disease;</em
                > <em
                  >pantothenate kinase-associated neurodegeneration (PKAN) and
                  organic acidemias; recessive dystrophic epidermolysis bullosa
                  (RDEB); and venous, lymphatic and mixed venolymphatic
                  malformations (VM, LM and VLM)</em
                >
              </p>
              <p>
                <em
                  >&#8211; Received positive opinion from the Committee for
                  Medicinal Products for Human Use (CHMP) recommending approval
                  in the European Union (EU) for</em
                ><em>
                  NULIBRY®(fosdenopterin) for the treatment of molybdenum
                  cofactor deficiency (MoCD) Type A</em
                >
              </p>
              <p>
                <em
                  >&#8211; Entered into exclusive license agreement with Bristol
                  Myers Squibb for BBP-398, a potentially best-in-class SHP2
                  inhibitor, in oncology; BridgeBio is eligible to receive up to
                  $905 million, including an upfront payment of $90 million
                  received during the quarter and up to $815 million in
                  additional milestone payments and royalties</em
                >
              </p>
              <p>
                <em
                  >&#8211; Announced sale of Priority Review Voucher (PRV) for
                  $110 million
                </em>
              </p>
              <p>
                <em
                  >&#8211; Secured a two-year deferral for first principal
                  payment on the Company’s senior debt</em
                >
              </p>
              <p>
                &#8211; <em>Ended quarter with </em><em>$688.6</em>
                <em
                  >million in cash, cash equivalents and marketable securities,
                  providing financial runway into 2024</em
                >
              </p>
              <p>
                <strong>PALO ALTO, CA – August 4, 2022 — </strong>BridgeBio
                Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a
                commercial-stage biopharmaceutical company focused on genetic
                diseases and cancers, today reported its financial results for
                the second quarter ended June 30, 2022, and provided an update
                on the Company’s operations.
              </p>
              <p>
                “Focused execution is our top priority, and we are delivering
                with positive proof-of-concept data in three of our key programs
                so far this year – achondroplasia, ADH1 and LGMD2i. At the same
                time, we’ve reported positive data for five additional
                early-to-mid-stage pipeline programs designed to target a range
                of genetic diseases with high unmet need. Our productive
                pipeline is bolstered by new value-creating partnerships, which
                we believe allow us to keep our attention fixed on driving
                forward the strongest science for patients,” said Neil Kumar,
                Ph.D., founder and CEO of BridgeBio.
              </p>
              <p><strong>BridgeBio’s Key Programs</strong></p>
              <p>
                <strong
                  >Low-dose infigratinib – FGFR1-3 inhibitor for achondroplasia
                  and hypochondroplasia</strong
                >
              </p>
              <ul>
                <li>
                  Positive interim results from Phase 2 trial of infigratinib
                  demonstrated a mean increase in annualized height velocity
                  (AHV) of 1.52 cm/year among all children 5 years of age and
                  older enrolled in Cohort 4 (dose: 128 mg/kg once daily)
                  (p=0.02, n=11), the highest dose level evaluated to date based
                  on longest available follow-up at time of data cut
                </li>
                <li>
                  The responder rate was 64% (7 of 11 children) in children 5
                  years and older enrolled in Cohort 4 (dose: 0.128 mg/kg once
                  daily), with response defined as ≥25% increase in AHV from
                  baseline
                </li>
                <li>
                  For the avoidance of doubt, the 1.52 cm/year AHV was
                  calculated based on all participants 5 years and older in
                  Cohort 4 and not just the responders
                </li>
                <li>
                  Given infigratinib’s profile to date, and after discussions
                  with regulators, BridgeBio has added a 5<sup>th</sup> cohort
                  to the trial and has begun dosing children in Cohort 5 (dose:
                  0.25 mg/kg once daily), with an expected readout of full data
                  at a medical conference in the first half of 2023
                </li>
                <li>
                  Infigratinib was well-tolerated with no serious adverse events
                  (SAE), no treatment-related ocular adverse events (AE) and no
                  discontinuations due to AEs including in Cohort 5 (dose: 0.25
                  mg/kg once daily) participants dosed to date, with a median
                  duration of follow-up of 48.1 weeks across all participants in
                  the study; only a limited number of AEs were assessed as
                  related to study drug and all were Grade 1, the lowest level
                </li>
                <li>
                  There were no dose or exposure-dependent serum phosphorus
                  elevations elevations; a single case of mild hyperphosphatemia
                  (Grade 1&lt;10% above upper limit of normal) led to a dose
                  reduction in a participant in Cohort 3 (dose: 0.064 mg/kg once
                  daily), the only dose adjustment made to date in the study,
                  and the participant continues at the lower dose without issue
                </li>
                <li>
                  As predicted based on preclinical data, BridgeBio began to see
                  efficacy in Cohort 4; also consistent with preclinical data,
                  the Company expects to see efficacy increase further in Cohort
                  5 as a result of the higher dose
                </li>
                <li>
                  Baseline AHV for Cohort 4 was 4.01 cm/year, which aligns with
                  expectations for natural history, and responder rates were
                  consistent irrespective of baseline AHV
                </li>
                <li>
                  Infigratinib is the only known oral product candidate
                  currently under clinical investigation for achondroplasia,
                  with issued patents and filed patent applications expected to
                  provide market protection as late as 2041
                </li>
                <li>
                  With more than 55,000 cases estimated in the United States
                  (US) and Europe, achondroplasia is the most common form of
                  genetic short stature and one of the most common genetic
                  conditions
                </li>
                <li>
                  BridgeBio expects to evaluate development of infigratinib in
                  other FGFR-driven skeletal dysplasias, which affect more than
                  50,000 people in the US and Europe, building on the positive
                  interim Phase 2 data in achondroplasia as well as preclinical
                  data in hypochondroplasia presented at the Endocrine Society’s
                  2022 annual meeting earlier this year
                </li>
                <li>
                  The Company expects to initiate its pivotal Phase 3 trial in
                  the first half of 2023
                </li>
              </ul>
              <p>
                <strong
                  >Encaleret – Calcium-sensing receptor (<em>CaSR</em>)
                  inhibitor for autosomal dominant hypocalcemia type 1
                  (ADH1)</strong
                >
              </p>
              <ul>
                <li>
                  The Company intends to initiate a Phase 3 pivotal study of
                  encaleret in patients with ADH1 by the end of 2022 and expects
                  to release topline data by year-end 2023
                </li>
                <li>
                  Positive data from BridgeBio’s Phase 2b study of encaleret in
                  ADH1 were shared in an
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/26dea3a5-ebc2-457f-953b-bc42712745d8"
                    >oral presentation</a
                  >
                  at the Endocrine Society’s 2022 annual meeting
                </li>
                <li>
                  The Phase 2b study demonstrated that treatment with encaleret
                  resulted in rapid and sustained restoration of normal mineral
                  homeostasis by day 5 of therapy which sustained at 24 weeks,
                  and encaleret was well-tolerated without any reported SAEs
                </li>
                <li>
                  If approved, encaleret could be the first therapy indicated
                  for the treatment of ADH1, a condition caused by
                  gain-of-function variants of the <em>CASR</em> gene estimated
                  to be carried by 12,000 individuals in the US alone
                </li>
                <li>
                  Granted and filed patents are expected to provide market
                  protection for encaleret in ADH1 into 2041
                </li>
              </ul>
              <p>
                <strong
                  >BBP-418 – Glycosylation substrate for limb-girdle muscular
                  dystrophy type 2i (LGMD2i)</strong
                >
              </p>
              <ul>
                <li>
                  BridgeBio engaged with regulatory health bodies to align on a
                  Phase 3 trial design and intends to initiate a Phase 3
                  clinical trial in the first half of 2023
                </li>
                <li>
                  Positive Phase 2 data were shared in a
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/b002afeb-1dda-4df5-916a-de212faf6939"
                    >poster presentation</a
                  >
                  at the Muscular Dystrophy Association (MDA) 2022 Annual
                  Meeting in March and in an
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/0b80bd70-8ae5-43cf-aaa0-941c09bac70e"
                    >oral presentation</a
                  >
                  at the International Congress on Neuromuscular Diseases
                  (ICNMD) in July
                </li>
                <li>
                  If proven to be successful, BBP-418 could be the first
                  approved therapy for patients with LGMD2i
                </li>
                <li>
                  Initial Phase 2 results indicate the potential for BBP-418 to
                  increase glycosylation of alpha-dystroglycan (αDG), which is
                  directly linked to the underlying disease mechanism, and to
                  drive consistent improvements of muscle function in patients
                  through the reduction of creatine kinase, a key marker of
                  muscle breakdown
                </li>
                <li>
                  90- and 180-day data show improvements on walk tests from
                  baseline, which BridgeBio believes suggests a potential impact
                  on clinical function and on the rate of disease progression
                </li>
              </ul>
              <p>
                <strong
                  >Acoramidis (AG10) – Transthyretin (TTR) stabilizer for
                  transthyretin amyloid cardiomyopathy (ATTR-CM)</strong
                >
              </p>
              <ul>
                <li>
                  Topline data from the Month 30 primary endpoint, a
                  hierarchical composite including all-cause mortality and
                  cardiovascular hospitalizations, of the ongoing Phase 3
                  ATTRibute-CM trial of acoramidis in ATTR-CM are expected in
                  mid-2023
                </li>
                <li>
                  In an
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/8201797c-6ecd-4f7a-a7ff-8a4d1a8b80b3"
                    >oral presentation</a
                  >
                  at the American College of Cardiology (ACC) Annual Scientific
                  Session &amp; Expo, BridgeBio shared updates on its data from
                  its ongoing Phase 2 open-label extension (OLE) study of
                  acoramidis in patients with ATTR-CM, which demonstrated that
                  acoramidis continued to be well-tolerated and to potently
                  stabilize TTR
                </li>
                <li>
                  NT-proBNP, a biomarker of cardiac failure and independent
                  predictor of mortality in ATTR-CM patients, was stable or
                  improving throughout the study and serum TTR levels were
                  sustainably increased from baseline at Month 30
                </li>
              </ul>
              <p>
                <strong
                  >BBP-631 – AAV5 gene therapy candidate for congenital adrenal
                  hyperplasia (CAH)</strong
                >
              </p>
              <ul>
                <li>
                  Initial Phase 1/2 data readout is anticipated by year-end 2022
                </li>
                <li>
                  With more than 75,000 patients estimated in the US and EU, CAH
                  is one of the most prevalent genetic diseases potentially
                  addressable with adeno-associated virus (AAV) gene therapy
                </li>
                <li>
                  The disease is caused by deleterious mutations in the gene
                  encoding an enzyme called 21-hydroxylase, leading to a lack of
                  endogenous cortisol production
                </li>
                <li>
                  BBP-631 is designed to provide a functional copy of the
                  21-hydroxylase-encoding gene (CYP21A2) and potentially address
                  many aspects of the disease course
                </li>
                <li>
                  If successful, BridgeBio’s investigational gene therapy would
                  be the first therapy for CAH to restore the body’s hormone and
                  steroid balance by enabling people with CAH to make their own
                  cortisol and aldosterone
                </li>
              </ul>
              <p><strong>RAS cancer portfolio</strong></p>
              <ul>
                <li>
                  BridgeBio has selected a next-generation KRAS G12C dual
                  inhibitor development candidate and plans to be in the clinic
                  in mid-2023. The Company’s development candidate is the
                  first-known small molecule that directly binds and inhibits
                  KRAS G12C in both its active (GTP bound) and inactive (GDP
                  bound) conformations. BridgeBio believes this will lead to
                  differentiated activity in cancer patients with KRAS G12C
                  driven disease as all other clinical stage KRAS G12C
                  inhibitors did not inhibit the active oncogenic form of the
                  protein (GTP-bound KRAS G12C)
                </li>
                <li>
                  BridgeBio is also pursuing PI3ka:RAS breakers, small molecules
                  that block RAS driven PI3Ka activation – a novel approach with
                  the potential to inhibit oncogenic PI3Ka signaling without
                  adverse effects on glucose metabolism
                </li>
                <li>
                  RAS is one of the most well-known oncogenic drivers with
                  approximately 30% of all cancers being driven by RAS
                  mutations, including large proportions of lung, colorectal and
                  pancreatic tumors
                </li>
              </ul>
              <p><strong>Recent Corporate Updates</strong></p>
              <ul>
                <li>
                  <strong
                    >Exclusive license agreement of up to $905 million with
                    Bristol Myers Squibb to develop and commercialize BBP-398, a
                    potentially best-in-class SHP2 inhibitor, in oncology: </strong
                  >Under the terms of the agreement, BridgeBio received an
                  upfront payment of $90 million from Bristol Myers Squibb and
                  is eligible to receive up to $815 million in development,
                  regulatory and sales milestone payments, and tiered royalties
                  in the low- to mid-teens. BridgeBio will retain the option to
                  acquire higher royalties in the US in connection with funding
                  a portion of development costs upon the initiation of
                  registrational studies. Based on the terms of the agreement,
                  BridgeBio continues to lead its ongoing Phase 1 monotherapy
                  and combination therapy trials. Bristol Myers Squibb will lead
                  and fund all other development and commercial activities.
                </li>
                <li>
                  <strong>Sale of PRV for $110 million: </strong>Entered into a
                  definitive agreement with an undisclosed purchaser to sell its
                  PRV for $110 million. The Company received the voucher in
                  February 2021 through the U.S. Food and Drug Administration
                  (FDA) approval of NULIBRY (fosdenopterin) for injection as the
                  first therapy to reduce the risk of mortality in patients with
                  MoCD Type A.
                </li>
                <li>
                  <strong
                    >Two-year extension for principal payment on senior debt: </strong
                  >Executed an amendment to the Company’s existing senior
                  secured credit facility. Amendment extended the interest-only
                  period by two years and principal repayment to November 17,
                  2026. BridgeBio retains access to up to $100 million in
                  delayed debt draws through year-end 2022, subject to certain
                  conditions. The amendment was approved unanimously by existing
                  lenders in the syndicate without adjusting pricing and without
                  imposing financial covenants.
                </li>
                <li>
                  <strong
                    >Positive Phase 1 data and Phase 2/3 trial design for GO
                    inhibitor for patients with primary hyperoxaluria type 1
                    (PH1) and recurrent kidney stone formers: </strong
                  >Positive data in a
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/e84c3b55-d92b-4d88-b2d1-eb4666e513e6"
                    >feature oral presentation</a
                  >
                  at the European Society for Pediatric Nephrology (ESPN 2022)
                  showed that BBP-711 led to near complete inhibition of
                  glycolate oxidase throughout the dosing period and greater
                  than 10-fold increases in plasma glycolate, suggesting it has
                  the potential to be both a best-in-class therapy and the first
                  oral therapy for PH1 and recurrent kidney stone formations.
                  Overproduction of oxalate in hyperoxaluria, including PH1 and
                  recurrent kidney stone formation with elevated oxalate, can
                  lead to kidney stone formation, nephrocalcinosis and renal
                  impairment. PH1 affects an estimated 5,000 patients in the US
                  and EU, while recurrent stone formers are much more common,
                  affecting an estimated 1.5 million individuals in the US and
                  EU. Based on the tolerability and potency of the oral therapy,
                  BridgeBio has met with regulators and intends to initiate a
                  Phase 2/3 pivotal study by the end of 2022. At the end of
                  2022, BridgeBio also intends to launch a Phase 2 study of
                  BBP-711 in adult recurrent kidney stone formers.
                </li>
                <li>
                  <strong
                    >Positive early data for investigational AAV9 gene therapy
                    in Canavan disease: </strong
                  >Promising pharmacodynamic data from the first two
                  participants dosed in the Phase 1/2 clinical trial of BBP-812
                  for the treatment of Canavan disease. Results showed
                  unprecedented decreases in N-acetylaspartate (NAA) in the
                  brain and urine, suggesting the therapy is producing
                  functional ASPA enzyme. Affecting approximately 1,000 children
                  in the US and EU, Canavan disease is an ultra-rare, disabling
                  and fatal disease with no approved therapy.
                </li>
                <li>
                  <strong
                    >Positive data in healthy volunteers to support BBP-671 for
                    pantothenate kinase-associated neurodegeneration (PKAN) and
                    organic acidemias:</strong
                  >
                  Positive interim Phase 1 data from healthy volunteers was
                  shared in a
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/d818ce7d-b47c-46a7-8bcc-e291b46608e7"
                    >scientific poster session</a
                  >
                  in support of the development of BBP-671 for PKAN and organic
                  acidemias at the Pan American Parkinson and Movement Disorders
                  (PAS) Congress. Results showed that BBP-671 was detected in
                  healthy volunteer plasma and cerebrospinal fluid, suggesting
                  that BBP-671 is entering the brain, a location critical to
                  target neurological complications of PKAN and organic
                  acidemias at their source. BBP-671 also increased whole blood
                  acetyl-coenzyme-A (CoA) levels in healthy volunteers, a signal
                  supporting proof of mechanism of the therapy. These data
                  represent, to the best of the Company’s knowledge, the first
                  time acetyl-CoA has been directly increased by a
                  pharmacological intervention in humans. Based on these data,
                  BridgeBio intends to move forward with the second part of the
                  Phase 1 clinical study in patients with propionic acidemia and
                  methylmalonic acidemia in the second half of 2022 and plans to
                  initiate a pivotal Phase 2/3 study in PKAN in 2023.
                </li>
                <li>
                  <strong
                    >Positive data from PTR-01 in patients with recessive
                    dystrophic epidermolysis bullosa (RDEB): </strong
                  >Shared updates on positive Phase 2 data in a
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/56f5b14a-ff20-4141-a255-21199abb3bb1"
                    >poster</a
                  >
                  at the Society for Investigative Dermatology (SID) Annual
                  Meeting 2022. Treatment with PTR-01 led to rapid, consistent,
                  and durable wound healing as observed in reduction of wound
                  surface area and clinician-reported assessments. All patients
                  that completed the study reported a decrease in pain over the
                  course of treatment with PTR-01.
                </li>
                <li>
                  <strong
                    >Positive preliminary data in patients with venous,
                    lymphatic and mixed venolymphatic malformations (VM, LM and
                    VLM):</strong
                  >
                  Positive Phase 1b data for VM, LM and VLM was shared in a
                  <a
                    href="https://investor.bridgebiodev.wpengine.com/static-files/dc3dbbd2-b3a8-4122-ad1d-3c63c185e717"
                    >virtual presentation</a
                  >
                  at the International Society for the Study of Vascular
                  Anomalies (ISSVA). Data showed that the investigational drug
                  was well-tolerated and showed a reduction of pS6 in lesions
                  from baseline to day 28.
                </li>
                <li>
                  <strong
                    >Positive opinion from CHMP for NULIBRY
                    (fosdenopterin):</strong
                  >
                  The CHMP of the European Medicines Agency (EMA) issued a
                  positive opinion recommending approval of NULIBRY in the EU
                  for the treatment of patients with MoCD Type A. Opinion is
                  based on the efficacy and safety data collected to date
                  compared to data from a natural history study. Under an
                  accelerated assessment pathway, a decision by the European
                  Commission (EC), which authorizes marketing approval in the
                  EU, is expected later this year. If approved by the EC,
                  NULIBRY would be the first and only approved therapy in the EU
                  to treat patients with MoCD type A, an ultra-rare,
                  life-threatening genetic disorder that often progresses
                  rapidly in infants with a median overall survival age of about
                  four years. NULIBRY was BridgeBio’s first FDA-approved
                  therapeutic. Sentynl Therapeutics, Inc. acquired global rights
                  to NULIBRY in March 2022.
                </li>
                <li>
                  <strong>Academic research collaborations:</strong> Initiated
                  an academic partnership with Baylor School of Medicine, and a
                  founding affiliation with Bakar Labs, the incubator at UC
                  Berkeley’s Bakar BioEnginuity Hub.
                </li>
              </ul>
              <p>
                <strong> </strong
                ><strong>Second Quarter 2022 Financial Results:</strong>
              </p>
              <p>
                <strong> </strong
                ><strong
                  >Cash, Cash Equivalents and Marketable Securities</strong
                >
              </p>
              <p>
                Cash, cash equivalents and marketable securities, excluding
                restricted cash, totaled $688.6 million as of June 30, 2022,
                compared to $787.5 million as of December 31, 2021. The net
                decrease of $98.9 million is primarily attributable to net cash
                used in operating activities of $191.1 million. The net cash
                used in operating activities was partially offset by a $90.0
                million in upfront payment received under the License,
                Development and Commercialization Agreement between the Company,
                its affiliate, Navire Pharma, Inc., and Bristol Myers Squibb
                (the “Navire-BMS License Agreement”). During the six months
                ended June 30, 2022, the Company also received upfront payments
                of $110.0 million from the sale of its priority review voucher
                and $10.0 million upon closing of an asset purchase agreement
                between its affiliate, Origin Biosciences, Inc., and Sentynl
                Therapeutics, Inc. The Company also made a $20.5 million
                mandatory prepayment of a portion of its term loan obligations
                under its Amended Loan and Security Agreement in connection with
                the upfront payment received from BMS.
              </p>
              <p>
                Cash, cash equivalents and marketable securities, excluding
                restricted cash, increased by $55.1 million when compared to the
                balance as of March 31, 2022 of $633.5 million. Net cash used in
                operating activities, which was partially offset by a $90.0
                million in upfront payment received from BMS, was $30.5 million
                for the three months ended June 30, 2022. Net cash used in
                operating activities was $160.6 million for the three months
                ended March 31, 2022.
              </p>
              <p><strong>Operating Costs and Expenses</strong></p>
              <p>
                Operating costs and expenses for the three and six months ended
                June 30, 2022 were $153.9 million and $329.3 million,
                respectively, as compared to $148.0 million and $316.0 million
                for the same periods in the prior year. The overall increase in
                operating costs and expenses for the three and six months ended
                June 30, 2022 compared to the comparative periods was due mainly
                to costs incurred related to the restructuring initiative that
                was started in the first quarter of 2022. Restructuring,
                impairment and related charges for the three and six months
                ended June 30, 2022 of $8.4 million and $31.1 million,
                respectively, were primarily comprised of impairments and
                write-offs of long-lived assets, severance and employee-related
                expenses, and exit costs. The Company continues to evaluate
                restructuring alternatives to drive operational changes in
                business processes, efficiencies, and cost savings.
              </p>
              <p>
                “We expect that operating expenses and cash burn will continue
                to decline meaningfully in the third and fourth quarters as
                restructuring charges decline and anticipated additional
                business development activity allows us to further decrease from
                this baseline. Cash on hand provides us with runway into 2024,”
                said Brian Stephenson, Ph.D., CFA, BridgeBio’s Chief Financial
                Officer.
              </p>
              <p>
                The Company’s research and development and other expenses have
                not been significantly impacted by the global COVID-19 pandemic
                for the periods presented. While BridgeBio experienced some
                delays in certain of its clinical enrollment and trial
                commencement activities, it continues to adapt with alternative
                site, telehealth and home visits, and at-home drug delivery, as
                well as mitigation strategies with its contract manufacturing
                organizations. The longer-term impact, if any, of COVID-19 on
                BridgeBio’s operating costs and expenses is currently
                unknown.<strong><br /> </strong>
              </p>
              <p>
                <img
                  fetchpriority="high"
                  decoding="async"
                  class="alignnone wp-image-5737 size-full"
                  src="../../wp-content/uploads/2022/08/BBIO_Q2_1.png"
                  alt=""
                  width="785"
                  height="780"
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_1.png         785w,
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_1-300x298.png 300w,
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_1-150x150.png 150w,
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_1-768x763.png 768w
                  "
                  sizes="(max-width: 785px) 100vw, 785px"
                />
              </p>
              <p>
                <img
                  decoding="async"
                  class="alignnone wp-image-5738 size-full"
                  src="../../wp-content/uploads/2022/08/BBIO_Q2_2.png"
                  alt=""
                  width="759"
                  height="640"
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_2.png         759w,
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_2-300x253.png 300w
                  "
                  sizes="(max-width: 759px) 100vw, 759px"
                />
              </p>
              <p>
                <img
                  decoding="async"
                  class="alignnone wp-image-5739 size-full"
                  src="../../wp-content/uploads/2022/08/BBIO_Q2_3-e1659614511302.png"
                  alt=""
                  width="786"
                  height="933"
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_3-e1659614511302.png         786w,
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_3-e1659614511302-253x300.png 253w,
                    https://bridgebio.com/wp-content/uploads/2022/08/BBIO_Q2_3-e1659614511302-768x912.png 768w
                  "
                  sizes="(max-width: 786px) 100vw, 786px"
                /><br />
                <img
                  decoding="async"
                  class="alignnone wp-image-5742"
                  src="../../wp-content/uploads/2022/08/earningspr-300x101.png"
                  alt=""
                  width="757"
                  height="255"
                  srcset="
                    https://bridgebio.com/wp-content/uploads/2022/08/earningspr-300x101.png 300w,
                    https://bridgebio.com/wp-content/uploads/2022/08/earningspr-768x259.png 768w,
                    https://bridgebio.com/wp-content/uploads/2022/08/earningspr.png         897w
                  "
                  sizes="(max-width: 757px) 100vw, 757px"
                />
              </p>
              <p><strong>About BridgeBio Pharma, Inc.</strong></p>
              <p>
                BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage
                biopharmaceutical company founded to discover, create, test and
                deliver transformative medicines to treat patients who suffer
                from genetic diseases and cancers with clear genetic drivers.
                BridgeBio’s pipeline of development programs ranges from early
                science to advanced clinical trials. BridgeBio was founded in
                2015 and its team of experienced drug discoverers, developers
                and innovators are committed to applying advances in genetic
                medicine to help patients as quickly as possible. For more
                information visit <a href="../../index.html"
                  ><strong>bridgebiodev.wpengine.com</strong></a
                > and follow us on <a
                  href="https://www.linkedin.com/company/bridgebio/"
                  ><strong>LinkedIn</strong></a
                > and <a href="https://twitter.com/BridgeBioPharma"
                  ><strong>Twitter</strong></a
                >.
              </p>
              <p>
                <strong
                  >BridgeBio Pharma, Inc. Forward-Looking Statements</strong
                >
              </p>
              <p>
                This press release contains forward-looking statements.
                Statements in this press release may include statements that are
                not historical facts and are considered forward-looking within
                the meaning of Section 27A of the Securities Act of 1933, as
                amended (the Securities Act), and Section 21E of the Securities
                Exchange Act of 1934, as amended (the Exchange Act), which are
                usually identified by the use of words such as “anticipates,”
                “believes,” “estimates,” “expects,” “intends,” “may,” “plans,”
                “projects,” “seeks,” “should,” “will,” and variations of such
                words or similar expressions. We intend these forward-looking
                statements to be covered by the safe harbor provisions for
                forward-looking statements contained in Section 27A of the
                Securities Act and Section 21E of the Exchange Act. These
                forward-looking statements, including statements relating to the
                clinical and therapeutic potential of our programs and product
                candidates, including the availability and success of complete
                data from our ongoing Phase 2 OLE of acoramidis in patients with
                symptomatic ATTR-CM, availability and success of topline results
                from Part B of our Phase 3 ATTRibute-CM trial of acoramidis, the
                availability and success of additional data from our ongoing
                Phase 2b study of encaleret for ADH1, the timing and success of
                additional trials of encaleret for ADH1, including the timing
                and announced design of a Phase 3 pivotal study of encaleret for
                ADH1, the availability and success of initial data from our
                ongoing Phase 2 study of low-dose infigratinib for
                achondroplasia and our ongoing Phase 1/2 study of BBP-631 for
                CAH, the timing and success of our RAS program, including the
                selection of a next-generation KRAS G12C dual inhibitor
                candidate and plans to be in the clinic in mid-2013, the
                availability and success of additional data from our ongoing
                Phase 2 study of BBP-418 for patients LGMD2i, the timing and
                success of regulatory discussions regarding potential paths to
                approval for BBP-418, the ability of BBP-418 to be the first
                approved therapy for patients with LGMD2i, the timing and
                success of a Phase 3 trial of BBP-418 in patients with LGMD2i,
                  the timing, success and announced design of our Phase 2/3
                trial for BBP-711 for PH1, the availability and success of
                additional data from our ongoing Phase 1/2 trial of BBP-812 for
                the treatment of Canavan disease, the availability and success
                of additional data from our ongoing Phase 1 study of BBP-671 for
                PKAN and organic acidemias, the availability and success of
                Phase 2 data for PTR-01 in patients with RDEB, the availability
                and success of Phase 1b data for VT30 topical gel (BBP-681) in
                patients with VM, LM and VLM, the success of our license
                agreement with Bristol Myers Squibb to develop and commercialize
                BBP-398, including our eligibility for development, regulatory
                and sales milestone payments and tiered royalties, the success
                of our asset purchase agreement with Sentynl Therapeutics,
                including our ability to achieve future milestone and royalty
                payments from Sentynl Therapeutics and the timing of these
                events and the timing and success of a potential decision by the
                EC on NULIBRY (fosdenopterin) for patients with MoCD type A
                based on a positive CHMP opinion for NULIBRY, the success of our
                academic partnership with Baylor School of Medicine and our
                founding affiliation with Bakar Labs, the success of our updated
                strategic collaboration with Helsinn Group, including our
                ability to achieve future milestone and royalty payments from
                Helsinn and the timing of these events, the timing and success
                of partnering and out-licensing discussions for certain programs
                in our pipeline, the timing and availability of delayed debt
                draws under our senior secured credit facility, the success of
                our reduction in operating expenses and our expectations for our
                operating expenses and cash burn for the second quarter, the
                success of our restructuring initiative and its savings being
                realized, as well as our anticipated cash runway, reflect our
                current views about our plans, intentions, expectations and
                strategies, which are based on the information currently
                available to us and on assumptions we have made. Although we
                believe that our plans, intentions, expectations and strategies
                as reflected in or suggested by those forward-looking statements
                are reasonable, we can give no assurance that the plans,
                intentions, expectations or strategies will be attained or
                achieved. Furthermore, actual results may differ materially from
                those described in the forward-looking statements and will be
                affected by a number of risks, uncertainties and assumptions,
                including, but not limited to, initial and ongoing data from our
                preclinical studies and clinical trials not being indicative of
                final data, the potential size of the target patient populations
                our product candidates are designed to treat not being as large
                as anticipated, the design and success of ongoing and planned
                clinical trials, future regulatory filings, approvals and/or
                sales, despite having ongoing and future interactions with the
                FDA or other regulatory agencies to discuss potential paths to
                registration for our product candidates, the FDA or such other
                regulatory agencies not agreeing with our regulatory approval
                strategies, components of our filings, such as clinical trial
                designs, conduct and methodologies, or the sufficiency of data
                submitted, the continuing success of our collaborations, the
                Company’s ability to unlock additional funding under our credit
                facility, potential volatility in our share price, potential
                adverse impacts due to the global COVID-19 pandemic such as
                delays in regulatory review, manufacturing and supply chain
                interruptions, adverse effects on healthcare systems and
                disruption of the global economy, as well as those risks set
                forth in the Risk Factors section of our Annual Report on
                Form 10-K for the year ended December 31, 2021 and our other
                filings with the U.S. Securities and Exchange Commission.
                Moreover, we operate in a very competitive and rapidly changing
                environment in which new risks emerge from time to time. These
                forward-looking statements are based upon the current
                expectations and beliefs of our management as of the date of
                this press release, and are subject to certain risks and
                uncertainties that could cause actual results to differ
                materially from those described in the forward-looking
                statements. Except as required by applicable law, we assume no
                obligation to update publicly any forward-looking statements,
                whether as a result of new information, future events or
                otherwise.
              </p>
              <p>
                <strong>BridgeBio Contact:</strong><br />
                Grace Rauh<br />
                <a
                  href="../../cdn-cgi/l/email-protection.html#cc8bbeadafa9e2beadb9a48caebea5a8aba9aea5a3a8a9bae2bbbca9a2aba5a2a9e2afa3a1"
                  ><span
                    class="__cf_email__"
                    data-cfemail="6a2d180b090f44180b1f022a0818030e0d0f0803050e0f1c441d1a0f040d03040f44090507"
                    >[email&#160;protected]</span
                  ></a
                ><br />
                (917) 232-5478
              </p>
              <p><strong> </strong></p>
            </section>
          </article>
        </div>
        <div class="flex-column one-three listing no-cap">
          <header class="intro">
            <h4><a href="../index.html" class="red uppercase">News</a></h4>
            <small class="date">08.04.2022</small>
            <hr />
            <p>
              <em>Hope through rigorous science</em> - medicines with
              transformative potential for patients with unmet needs.
            </p>
            <p>
              <a href="../../about-us/index.html" class="button">Our Mission</a>
            </p>
          </header>
        </div>
      </div>
    </main>

    <footer class="footer">
      <div class="content-form text-center">
        <h2>join our mailing list</h2>
        <p class="stay-informed">
          Stay informed on everything that is happening at BridgeBio.
        </p>
        <button
          type="button"
          class="button sign-up-button button--secondary-blue"
        >
          <span>SIGN UP</span>
          <img
            src="../../wp-content/themes/bridgebio/assets/img/icons/chevron-down-light.svg"
            width="24px"
            alt=""
          />
        </button>
        <div class="content-form">
          <p class="thank-you-message">Thanks for submitting the form.</p>
          <script
            data-cfasync="false"
            src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
          ></script>
          <script src="../../../pages.bridgebio.com/js/forms2/js/forms2.min.js"></script>
          <form id="mktoForm_8"></form>
          <script>
            MktoForms2.loadForm(
              "//pages.bridgebio.com",
              "848-KYN-928",
              8,
              function (form) {
                MktoForms2.whenRendered(function (form) {
                  console.log(form);
                  let formElement = form.getFormElem()[0];
                  let resizeTimeout;

                  function onResize() {
                    // Clear the previous timeout if it exists
                    if (resizeTimeout) {
                      clearTimeout(resizeTimeout);
                    }
                    // Set a new timeout to delay the execution
                    resizeTimeout = setTimeout(() => {
                      Array.from(formElement.querySelectorAll("[style]"))
                        .concat(formElement)
                        .forEach((element) => {
                          element.removeAttribute("style");
                        });
                    }, 100); // Delay of 100 milliseconds
                  }
                  // Add the event listener for the resize event
                  window.addEventListener("resize", onResize);
                  // Initial call to set content based on initial size
                  onResize();
                });
                MktoForms2.whenReady(function (form) {
                  form.onSuccess(function (values, followUpUrl) {
                    // Custom onFormSubmitted code
                    let pageCenter = document.querySelector(".content-form");

                    pageCenter.classList.add("form-thank-you");

                    if (pageCenter) {
                      pageCenter.scrollIntoView({
                        behavior: "smooth",
                        block: "center",
                      });
                    }
                    return false;
                  });
                });
              }
            );
          </script>
        </div>
      </div>

      <div class="footer-bottom-container">
        <div class="footer-top">
          <p class="form-container__phrase">
            Follow us on LinkedIn, Twitter, Facebook, and YouTube for the latest
            news.
          </p>
          <a
            href="https://www.linkedin.com/company/bridgebio"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="linkedin">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM19.5392 15.9149C21.6017 15.9149 21.6018 17.8688 21.6018 19.2953V25.5094H25.5626V18.4979C25.5626 16.464 25.2943 15.1309 24.6918 14.1743C23.9502 12.997 22.6808 12.4246 20.8124 12.4246C20.0597 12.3996 19.3141 12.5779 18.6542 12.9409C17.9943 13.3038 17.4444 13.8378 17.0624 14.4868H17.0067V12.7487H13.205V25.5128H17.165V19.192C17.1666 17.573 17.4451 15.9149 19.5392 15.9149ZM6.74992 12.7487V25.5128H10.7152V12.7487H6.74992ZM8.7299 6.39373C8.27257 6.39159 7.82483 6.52538 7.44369 6.77811C7.06255 7.03084 6.76516 7.39111 6.5892 7.81318C6.41323 8.23525 6.36698 8.70008 6.45573 9.14866C6.54449 9.59724 6.76421 10.0093 7.08765 10.3326C7.4111 10.6559 7.82347 10.8758 8.27214 10.9644C8.72081 11.053 9.18593 11.0062 9.608 10.8301C10.0301 10.654 10.3901 10.3565 10.6427 9.97534C10.8954 9.59416 11.0292 9.14652 11.0269 8.68925C11.0266 8.08079 10.785 7.49725 10.3551 7.06661C9.92515 6.63597 9.3417 6.39339 8.73316 6.39207L8.7299 6.39373Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://twitter.com/BridgeBioPharma"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="x">
                <path
                  id="Vector"
                  d="M24.3333 29.3297H7.66667C6.341 29.3284 5.07013 28.8013 4.13274 27.864C3.19534 26.9268 2.668 25.6559 2.66667 24.3304V7.66606C2.668 6.34057 3.19534 5.06974 4.13274 4.13247C5.07013 3.19521 6.341 2.66807 7.66667 2.66675H24.3333C25.659 2.66807 26.9299 3.19521 27.8673 4.13247C28.8047 5.06974 29.332 6.34057 29.3333 7.66606V24.3304C29.332 25.6559 28.8047 26.9268 27.8673 27.864C26.9299 28.8013 25.659 29.3284 24.3333 29.3297ZM14.8257 17.9363L19.3683 24.5462H24.3333L17.5833 14.7276L23.7869 7.51691H22.3167L16.931 13.7769L12.6268 7.51691H7.66667L14.1742 16.9848L7.66667 24.5462H9.13681L14.8257 17.9363ZM22.3208 23.4914H20.0625L15.5715 17.0689L14.9132 16.1257L9.6674 8.62676H11.9257L16.1591 14.6801L16.8175 15.6233L22.3176 23.493L22.3208 23.4914Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.facebook.com/profile.php?id=61561087329761"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="facebook">
                <path
                  id="Vector"
                  d="M22.095 29.3534C19.4 29.3534 15.9527 29.3468 12.9369 29.3401H11.1282C8.93901 29.3351 7.04516 29.3309 6.13265 29.3309C5.59766 29.3309 5.52602 29.3309 5.52352 29.3309C4.76602 29.3301 4.03964 29.0287 3.50407 28.4931C2.96851 27.9574 2.66733 27.2312 2.66667 26.4738V5.52335C2.66733 4.76595 2.96851 4.03975 3.50407 3.50411C4.03964 2.96846 4.76602 2.66714 5.52352 2.66626H26.4757C27.2333 2.66692 27.9598 2.96816 28.4955 3.50383C29.0313 4.03949 29.3327 4.76581 29.3333 5.52335V26.473C29.3327 27.2305 29.0313 27.9569 28.4955 28.4925C27.9598 29.0282 27.2333 29.3294 26.4757 29.3301C26.4165 29.3459 24.9808 29.3534 22.095 29.3534ZM10.4283 13.9105V17.6775H13.7376V26.7838H17.8115V17.6784H20.8482L21.4268 13.9114H17.8123V11.4667C17.7896 10.9593 17.9512 10.4608 18.2669 10.0628C18.4813 9.84172 18.7417 9.67061 19.0298 9.5616C19.3178 9.45258 19.6264 9.40833 19.9335 9.43199H21.5766V6.22409C20.6118 6.06851 19.637 5.98358 18.6599 5.96997C18.0062 5.93934 17.353 6.03949 16.7385 6.26455C16.1241 6.48961 15.5608 6.83505 15.0816 7.28062C14.6195 7.78711 14.2627 8.38034 14.0318 9.02586C13.8009 9.67138 13.7008 10.3563 13.7368 11.0409V13.9147L10.4283 13.9105Z"
                  fill="black"
                />
              </g>
            </svg>
          </a>
          <a
            href="https://www.youtube.com/@BridgeBioPharma-u2b"
            target="_blank"
            class="form-container__social-link"
          >
            <svg
              width="32"
              height="32"
              viewBox="0 0 32 32"
              fill="none"
              xmlns="http://www.w3.org/2000/svg"
            >
              <g id="youtube">
                <g id="Subtract">
                  <path
                    d="M19.4085 15.3332L13.8662 12.1908V18.4755L19.4085 15.3332Z"
                    fill="black"
                  />
                  <path
                    fill-rule="evenodd"
                    clip-rule="evenodd"
                    d="M5.33317 2.6665C3.86041 2.6665 2.6665 3.86041 2.6665 5.33317V26.6665C2.6665 28.1393 3.86041 29.3332 5.33317 29.3332H26.6665C28.1393 29.3332 29.3332 28.1393 29.3332 26.6665V5.33317C29.3332 3.86041 28.1393 2.6665 26.6665 2.6665H5.33317ZM24.3361 8.43791C25.2546 8.67936 25.9763 9.3882 26.2222 10.2902H26.2204C26.6665 11.9235 26.6665 15.3332 26.6665 15.3332C26.6665 15.3332 26.6665 18.7429 26.2204 20.3761C25.9746 21.2781 25.2528 21.987 24.3344 22.2284C22.6713 22.6665 15.9998 22.6665 15.9998 22.6665C15.9998 22.6665 9.32834 22.6665 7.6653 22.2284C6.74685 21.987 6.02508 21.2781 5.77922 20.3761C5.33317 18.7429 5.33317 15.3332 5.33317 15.3332C5.33317 15.3332 5.33317 11.9235 5.77922 10.2902C6.02508 9.3882 6.74685 8.67936 7.6653 8.43791C9.32834 7.99984 15.9998 7.99984 15.9998 7.99984C15.9998 7.99984 22.6713 7.99984 24.3361 8.43791Z"
                    fill="black"
                  />
                </g>
              </g>
            </svg>
          </a>
        </div>

        <div class="footer__contact">
          <p class="bold">
            &copy; 2024 BridgeBio Inc. All rights reserved. |
            <a href="https://investor.bridgebio.com/" target="_blank"
              >For Investors</a
            >
            | <a href="../../careers/index.html">careers</a> |
            <a href="../../terms-of-use/index.html">terms of use</a> |
            <a href="../../bridgebio-global-privacy-policy/index.html"
              >privacy policy</a
            >
            |
            <a href="../../cookies-notice/index.html">cookies&nbsp;notice</a> |
            <a href="../../us-expanded-access-policy/index.html"
              >us&nbsp;expanded&nbsp;access&nbsp;policy</a
            >
            | <a href="../../contact-us/index.html">contact us</a> |
            <a href="../../sms-policy/index.html">sms&nbsp;policy</a> |
            <a href="../../social-policy.html">social policy</a>
          </p>
          <p>
            3160 Porter Drive, Suite 250, Palo Alto, CA, 94304 | 650-391-9740 |
            <a
              href="../../cdn-cgi/l/email-protection.html#7f161119103f1d0d161b181a1d1610511c1012"
              ><span
                class="__cf_email__"
                data-cfemail="98f1f6fef7d8faeaf1fcfffdfaf1f7b6fbf7f5"
                >[email&#160;protected]</span
              ></a
            >
            | MAT-AS—0001
          </p>
        </div>
      </div>
    </footer>

    <script
      data-cfasync="false"
      src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"
    ></script>
  </body>
</html>
